Kyowa grants Oxford BioTherapeutics exclusive, worldwide rights from its BioWa Inc. subsidiary to use its Potelligent technology to Oxford's antibodies for cancer

Kyowa Hakko Kirin Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Oxford BioTherapeutics Ltd.

U.K. / Tools, Services, and Manufacturing

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced